Plant Name: Hedera helix
Taxonomic Information:
Plant ID: NPO11192
Plant Latin Name: Hedera helix
Taxonomy Genus: Hedera
Taxonomy Family: Araliaceae
Plant External Links:
NCBI TaxonomyDB:
4052
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; Lebanon; Italy; India; SpainTraditional Medicine System:
Medicinal Functions:
Antibacterial; Antirheumatic; Antiseptic; Antispasmodic; Astringent; Cathartic; Diaphoretic; Emetic; Emmenagogue; Parasiticide; Skin; Stimulant; Vasoconstrictor; Vasodilator; Vermifuge
Geographical Distribution:
Lebanon; Italy; Turkey; India; Spain
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2C; ADRA2A; | |
| RBBP9; MTOR; | |
| SLC2A1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | RBBP9 | Putative hydrolase RBBP9 | O75884 | CHEMBL1075121 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| SLC superfamily of solute carriers | SLC2A1 | Glucose transporter | P11166 | CHEMBL2535 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 4.971E-08 | 1.082E-03 | ADRA2A, ADRA2C, MTOR |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 3.216E-07 | 1.751E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 3.216E-07 | 1.751E-03 | ADRA2A, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.608E-07 | 1.751E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 1.500E-06 | 3.629E-03 | ADRA2A, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.500E-06 | 3.629E-03 | ADRA2A, ADRA2C |
| BP | GO:0023052; signaling | GO:0050796; regulation of insulin secretion | 6.848E-06 | 1.012E-02 | ADRA2A, ADRA2C, SLC2A1 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.357E-04 | 7.240E-02 | ADRA2A, ADRA2C, MTOR, SLC2A1 |
| MF | GO:0005488; binding | GO:0019900; kinase binding | 3.772E-04 | 9.777E-02 | ADRA2A, MTOR, SLC2A1 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.049E-04 | 1.670E-01 | ADRA2A, SLC2A1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 3.463E-03 | 3.625E-01 | ADRA2A, ADRA2C, SLC2A1 |
| CC | GO:0044464; cell part | GO:0005737; cytoplasm | 8.870E-03 | 6.078E-01 | ADRA2A, ADRA2C, MTOR, RBBP9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.098E-04 | 1.739E-03 | SLC2A1, MTOR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 1.199E-04 | 1.739E-03 | SLC2A1, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.600E-04 | 1.979E-03 | SLC2A1, MTOR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.912E-04 | 1.979E-03 | SLC2A1, MTOR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 3.412E-04 | 1.979E-03 | SLC2A1, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 6.817E-04 | 3.295E-03 | ADRA2C, ADRA2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.859E-03 | 7.703E-03 | ADRA2C, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.778E-03 | 1.369E-02 | SLC2A1, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.615E-02 | 3.396E-02 | MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.491E-02 | 3.396E-02 | MTOR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA2A; ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ADRA2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
